Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -1.41
- Piotroski Score 3.00
- Grade Buy
- Symbol (STRO)
- Company Sutro Biopharma, Inc.
- Price $2.55
- Changes Percentage (0.79%)
- Change $0.02
- Day Low $2.45
- Day High $2.60
- Year High $6.13
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/24/2025
- Fiscal Year End N/A
- Average Stock Price Target $11.00
- High Stock Price Target $15.00
- Low Stock Price Target $8.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.88
- Trailing P/E Ratio -1.97
- Forward P/E Ratio -1.97
- P/E Growth -1.97
- Net Income $-106,793,000
Income Statement
Quarterly
Annual
Latest News of STRO
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Investors in Eagle Eye Solutions Group (LON:EYE) have seen strong returns of 188% over the past five years
Investing in stocks can result in losing all your money or gaining over 100%. Eagle Eye Solutions Group plc stock has seen an impressive 188% increase in the last five years. Analyzing its fundamental...
By Yahoo! Finance | 12 hours ago -
Drug "several times" stronger than fentanyl linked to California overdose death
The U.S. Department of Justice in Los Angeles filed charges in the first death-related criminal case involving the synthetic opioid protonitazene. 21-year-old Benjamin Collins faces a minimum 20-year ...
By CBS News | 12 hours ago -
Indian rupee weakens to record low, hurt by persistent outflows, stronger dollar
The Indian rupee reached a new low due to a strong dollar, ongoing portfolio outflows, and geopolitical tensions. The Reserve Bank of India's intervention helped stabilize the currency. Foreign invest...
By Yahoo! Finance | 14 hours ago
